1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
3Department of Radiation Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
Copyright © 2014 by the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | No. | 5-Year rate (%) | p-value |
---|---|---|---|
Gender | |||
Male | 11 | 91 | 0.4132 |
Female | 6 | 67 | |
Age (yr) | |||
< 60 | 13 | 76 | 0.3320 |
≥ 60 | 14 | 100 | |
Tumor size (cm) | |||
< 2 | 5 | 80 | 0.7369 |
≥ 2 | 12 | 81 | |
Distance from AV (cm) | |||
< 3 | 7 | 69 | 0.1434 |
≥ 3 | 10 | 90 | |
Histologic grade | |||
Well | 5 | 60 | 0.2056 |
Moderate | 11 | 100 | |
Clinical N-classification | |||
0 | 15 | 87 | 0.2018 |
1 | 2 | 100 | |
Chemotherapya) | |||
5-FU | 9 | 100 | 0.0298 |
Capecitabine | 7 | 54 | |
ypT-classification | |||
0 | 10 | 90 | 0.1643 |
1-2 | 7 | 69 |
Characteristic | No. (%) |
---|---|
Distance from anal verge (cm) | |
Median | 3 |
Range | 1-6 |
Histologic grade | |
Well | 5 (29) |
Moderate | 11 (65) |
Unknown | 1 (6) |
Clinical N-classification | |
N0 | 15 (88) |
N1 | 2 (12) |
Tumor size (cm) | |
Median | 2.0 |
Range | 1.4-4.0 |
Serum carcinoembryonic antigen (ng/mL) | |
Median | 1.3 |
Range | 0.7-30.6 |
Characteristic | ypT0 (n=10) | ypT1-2 (n=7) |
---|---|---|
Gender | ||
Male | 6 | 5 |
Female | 4 | 2 |
Median age (yr) | 64 (38-79) | 53 (41-64) |
Median pre-CRT CEA (ng/mL) | 1.4 (0.8-4.5) | 1.1 (0.7-30.6) |
Median post-CRT CEA (ng/mL) | 1.1 (0.5-5.0) | 1.8 (0.3-3.0) |
Histologic grade (pre-CRT) | ||
Well | 2 | 3 |
Moderate | 8 | 3 |
Clinical N-classification | ||
0 | 10 | 5 |
1 | 0 | 2 |
Chemotherapy (preoperative) | ||
5-FU | 6 | 3 |
Capecitabine | 4 | 3 |
S-1+irinotecan | 0 | 1 |
Chemotherapy (postoperative) | ||
5-FU (+leucovorin) | 3 | 5 |
No | 7 | 2 |
Age (yr) | Gender | AV (cm) | Grade | cN | Preoperative chemotherapy | ypT | Postoperative chemotherapy | Site of failure | DFS (mo) |
---|---|---|---|---|---|---|---|---|---|
53 | Male | 6 | Well | 0 | Capecitabine | 1 | 5-FU | Distant | 14 |
49 | Female | 1 | Well | 0 | Capecitabine | 0 | 5-FU | Locoregional | 14 |
41 | Female | 2 | Unknown | 1 | Capecitabine | 1 | 5-FU | Distant | 43 |
62 | Male | 2 | Moderate | 0 | 5-FU | 1 | No | Locoregional | 93 |
Variable | No. | 5-Year rate (%) | p-value |
---|---|---|---|
Gender | |||
Male | 11 | 91 | 0.4132 |
Female | 6 | 67 | |
Age (yr) | |||
< 60 | 13 | 76 | 0.3320 |
≥ 60 | 14 | 100 | |
Tumor size (cm) | |||
< 2 | 5 | 80 | 0.7369 |
≥ 2 | 12 | 81 | |
Distance from AV (cm) | |||
< 3 | 7 | 69 | 0.1434 |
≥ 3 | 10 | 90 | |
Histologic grade | |||
Well | 5 | 60 | 0.2056 |
Moderate | 11 | 100 | |
Clinical N-classification | |||
0 | 15 | 87 | 0.2018 |
1 | 2 | 100 | |
Chemotherapy |
|||
5-FU | 9 | 100 | 0.0298 |
Capecitabine | 7 | 54 | |
ypT-classification | |||
0 | 10 | 90 | 0.1643 |
1-2 | 7 | 69 |
CRT, chemoradiotherapy; CEA, carcinoembrynonic antigen; 5-FU, 5-fluorouracil.
AV, anal verge; DFS, disease-free survival; 5-FU, 5-fluorouracil.
AV, anal verge; 5-FU, 5-fluorouracil. The patient who received S-1 plus irinotecan was excluded from comparison.